- Home
- ICLR vs GNTA Comparison
ICLR vs GNTA Comparison
Compare ICLR & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- GNTA
- Stock Information
- Founded
- ICLR 1990
- GNTA 2014
- Country
- ICLR Ireland
- GNTA Italy
- Employees
- ICLR N/A
- GNTA N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICLR Health Care
- GNTA Health Care
- Exchange
- ICLR Nasdaq
- GNTA Nasdaq
- Market Cap
- ICLR 11.5B
- GNTA 70.8M
- IPO Year
- ICLR 1998
- GNTA 2021
- Fundamental
- Price
- ICLR $133.96
- GNTA $4.25
- Analyst Decision
- ICLR Buy
- GNTA Strong Buy
- Analyst Count
- ICLR 12
- GNTA 1
- Target Price
- ICLR $206.64
- GNTA $25.00
- AVG Volume (30 Days)
- ICLR 2.1M
- GNTA 6.8K
- Earning Date
- ICLR 04-30-2025
- GNTA 01-01-0001
- Dividend Yield
- ICLR N/A
- GNTA N/A
- EPS Growth
- ICLR 11.53
- GNTA N/A
- EPS
- ICLR 9.19
- GNTA N/A
- Revenue
- ICLR $8,192,621,999.00
- GNTA N/A
- Revenue This Year
- ICLR $1.63
- GNTA N/A
- Revenue Next Year
- ICLR $4.82
- GNTA N/A
- P/E Ratio
- ICLR $15.07
- GNTA N/A
- Revenue Growth
- ICLR N/A
- GNTA N/A
- 52 Week Low
- ICLR $133.28
- GNTA $2.79
- 52 Week High
- ICLR $347.72
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- ICLR 33.96
- GNTA 60.49
- Support Level
- ICLR $135.00
- GNTA $3.92
- Resistance Level
- ICLR $141.96
- GNTA $4.25
- Average True Range (ATR)
- ICLR 6.69
- GNTA 0.21
- MACD
- ICLR 0.43
- GNTA 0.04
- Stochastic Oscillator
- ICLR 3.63
- GNTA 100.00
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.